Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Vitamins E And C Trial Shows No CVD-Prevention Benefits In “Healthy” Men

This article was originally published in The Tan Sheet

Executive Summary

A study finding no link between vitamin E or vitamin C supplementation and cardiovascular disease prevention in men was conducted using subjects largely regarded as healthy - a population that supplement industry stakeholders have called the true measuring stick for evaluating nutrient benefits

You may also be interested in...



Research & Development In Brief

Trade groups contest negative ginkgo study: A recently published study that found ginkgo biloba does not slow cognitive decline in older adults "should not be viewed as the final word" on the supplement's benefit, the Council for Responsible Nutrition argues. "There is a large body of previously published evidence" and ongoing clinical trials that suggest "ginkgo may improve cognitive impairment in older adults," says CRN VP of Scientific and Regulatory Affairs Douglas MacKay in a Dec. 29 statement. The study, published in the Journal of the American Medical Association, found the annual rates of decline of memory, attention, visual-spatial abilities, language and executive function of the 1,545 participants who took a 120-mg dose of ginkgo twice daily were the same as for 1,524 participants who took a placebo for an average of 6.1 years. The study, led by Beth Snitz at the Neurology Department at the University of Pittsburgh, is a secondary analysis of the Ginkgo Evaluation of Memory study, originally published in November 2008. The American Herbal Products Association complains the data review had "the same limitations as the original GEM study" and was not "ideally suited for this new endpoint.

Research & Development In Brief

Trade groups contest negative ginkgo study: A recently published study that found ginkgo biloba does not slow cognitive decline in older adults "should not be viewed as the final word" on the supplement's benefit, the Council for Responsible Nutrition argues. "There is a large body of previously published evidence" and ongoing clinical trials that suggest "ginkgo may improve cognitive impairment in older adults," says CRN VP of Scientific and Regulatory Affairs Douglas MacKay in a Dec. 29 statement. The study, published in the Journal of the American Medical Association, found the annual rates of decline of memory, attention, visual-spatial abilities, language and executive function of the 1,545 participants who took a 120-mg dose of ginkgo twice daily were the same as for 1,524 participants who took a placebo for an average of 6.1 years. The study, led by Beth Snitz at the Neurology Department at the University of Pittsburgh, is a secondary analysis of the Ginkgo Evaluation of Memory study, originally published in November 2008. The American Herbal Products Association complains the data review had "the same limitations as the original GEM study" and was not "ideally suited for this new endpoint.

Research & Development In Brief

Trade groups contest negative ginkgo study: A recently published study that found ginkgo biloba does not slow cognitive decline in older adults "should not be viewed as the final word" on the supplement's benefit, the Council for Responsible Nutrition argues. "There is a large body of previously published evidence" and ongoing clinical trials that suggest "ginkgo may improve cognitive impairment in older adults," says CRN VP of Scientific and Regulatory Affairs Douglas MacKay in a Dec. 29 statement. The study, published in the Journal of the American Medical Association, found the annual rates of decline of memory, attention, visual-spatial abilities, language and executive function of the 1,545 participants who took a 120-mg dose of ginkgo twice daily were the same as for 1,524 participants who took a placebo for an average of 6.1 years. The study, led by Beth Snitz at the Neurology Department at the University of Pittsburgh, is a secondary analysis of the Ginkgo Evaluation of Memory study, originally published in November 2008. The American Herbal Products Association complains the data review had "the same limitations as the original GEM study" and was not "ideally suited for this new endpoint.

Related Content

Topics

UsernamePublicRestriction

Register

PS102319

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel